Genovis AB has signed a strategic cooperation agreement with Alphalyse A/S

The cooperation agreement will provide Genovis with access to Alphalyse’s
expertise in mass spectrometry while Alphalyse will have the opportunity to
offer its customers analyses based on Genovis’ unique enzymes for antibodies and
other pharmaceutical proteins.
Much of Genovis’ customer base works with mass spectrometry in the analysis of
biologics. Genovis and Alphalyse will actively market new methods based on
Genovis’ products, which directly focus on this customer group. This strategy
will strengthen Genovis, which will be able to expand its customer base and thus
increase sales.

“Alphalyse has world-leading expertise in mass spectrometric analysis of
proteins. Their knowledge of sample processing and the limitations of current
enzymes enable us to use existing and upcoming products in applications where
they will have maximum value. We are very pleased to have the opportunity to
market and develop methods of mass spectrometric analysis together with
Alphalyse and I am convinced that this will be a long-term and mutually
rewarding collaboration,” says Fredrik Olsson, CEO of Genovis.

“Genovis has unique enzymes and products that allow for better and faster
analysis of protein-based drugs when using mass spectrometry. The collaboration
with Genovis provides Alphalyse with a major advantage in our work helping
pharmaceutical companies that develop products such as monoclonal antibodies,
antibody drug conjugates for cancer treatment and de-novo-sequencing of new
antibodies in the discovery phase,” says Ejvind Mørtz, COO of Alphalyse.

MORE ABOUT ALPHALYSE

Alphalyse is a contract research company (CRO) with cutting-edge expertise in
mass spectrometry-based protein analysis for research, production and clinical
development of native and recombinant proteins. Through its PICK 'n POST™
protein analysis services and customized analytical services, the company offers
a range of unique high-quality protein analyses to identify and characterize
biopharmaceutical proteins such as monoclonal antibodies and vaccines. The
services are used by the biotech industry, pharmaceutical companies and academic
research groups worldwide. Alphalyse has offices in Odense, Denmark and Palo
Alto, California, USA.

MORE ABOUT GENOVIS PRODUCTS

Genovis’ products are marketed under the name “Smart Enzymes” and are used to
process antibodies and split them into smaller fragments. To date, the products
have been marketed primarily for characterization of biologics. Customers use
small quantities of the products in a large number of samples to divide the drug
candidate into smaller fragments, which are then analyzed. All of the products
are also highly effective in production of large quantities of antibody
fragments, which are required in several different studies in preclinical drug
discovery.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc.
(USA).

Genovis shares are listed on Nasdaq First North Stockholm, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.